Meridian Launches a New Inhibitor Tolerant qPCR Reagent to Significantly Simplify Molecular Diagnostic Workflows From Crude Samples
CINCINNATI, April 18, 2019 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of its Inhibitor-tolerant qPCR Mix, a novel mix to accelerate workflows and improve DNA target amplification and quantification from crude samples; adding to its growing portfolio of molecular diagnostic products.
A variety of different inhibitors inherent to clinical and environmental samples can negatively impact the sensitivity and accuracy of a molecular assay. To overcome this, specimens often have to undergo extensive processing prior to testing. However, extraction technologies are slow and time consuming, impacting the amount of target nucleic acid available for testing and some enzyme inhibitors can co-elute following purification and induce false-negative assay results.
Inhibitor-tolerant qPCR Mix contains a novel DNA polymerase and buffer system, that is designed to reduce the amount of sample processing required for reliable qPCR analysis and can be used for amplification from crude lysates or inhibitor-rich samples such as urine, saliva, cerebral spinal fluid (CSF), whole blood, serum, plasma, feces and plants samples. This makes Inhibitor-tolerant qPCR Mix ideally suited for applications in cancer research, infectious disease, as well as GMO testing, foodborne and waterborne pathogen detection.
Dr. Florent Chang-Pi-Hin, Director, Research and Development, commented, “With the Inhibitor-tolerant qPCR Mix we are giving our customers a highly sensitive qPCR mix for use on crude samples. Removing the need for DNA purification not only reduces the time to results, but also the cost of extraction, while still allowing detection of very low copy number targets.”
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
Chief Executive Officer
Meridian Bioscience, Inc.